Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial

Executive Summary

The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.

You may also be interested in...



Cardiovascular Catch-Up: Cardiac Implants Puts Ring Around Tricuspid Annulus; Boston Scientific’s Acurate neo2 TAVR Progresses; Medtronic Promotes New Stroke Plan

This edition of Medtech Insight’s regular round-up of some recent cardiovascular technology news and conversations you may have missed, including updates from Cardiac Implants, Boston Scientific, HeartBeam and Medtronic.

Minute Insight: HeartFlow Drops SPAC Plan; Names New Leadership

John Farquhar, who served as HeartFlow’s COO since August 2021, will now lead the cardiac imaging company as CEO. The move comes just weeks after HeartFlow terminated plans to go public through a merger with a special purpose acquisition company.

Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance

In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel